CAS: 26921-17-5; (S)-Timolol Maleate

该化合物是主要用于治疗青光眼和眼部高血压的选择性乙型肾上腺受体对抗剂,作为Timololol的(S)-抗生素,与种族混合物相比,它具有优越的药理活动,在较低剂量下提高了功效,其脊髓盐形式提高了溶性,提高了稳定性,有助于形成眼科溶液.该化合物通过减少水性幽默生产,有效地减少了内心压力. (S)-Timolol Maleate的特点是高纯度和持续性能,使它成为用于眼科应用的可靠活性药物成分,其完善的安全特征和有针对性的行动机制强调了其在临床环境中的实用性.

结构式图片

欧盟法规

C&L通报REACH预注册

上下游产品

CAS号30165-97-0 4-吗啉-4-基-1,2,5-... | CAS号58827-68-2 rac4-[4-(环氧乙烷基甲... | CAS号56526-15-9 (S)-5-((4-morph... | CAS号30165-96-9 3-氯-4-吗啉基-1,2,5-噻二唑 | CAS号69500-53-4 (S)-4-[4-(Oxira... | CAS号85665-60-7 3-(1,1-Dimethyl... | CAS号26839-75-8 噻吗洛尔 | CAS号110-16-7 马来酸

合成工艺路线路线简述

  • 合成目标产物 (S)-Timolol Maleate 主要起始原料 3-Chloro-4-Morpholino-1,2,5-Thiadiazole
  • (文献来源)合成步骤主要原料 3-Chloro-4-Morpholino-1,2,5-Thiadiazole

海关参考信息

专利信息


专利号:US-10925977-B2
优先权日:2006-10-05
标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:WO-2009070154-A1
优先权日:2007-11-26
标 题 :Direct vapor phase process for synthesis of microspheres in network of nanowires
发明人:HULLAVARAD SHIVA S; HULLAVARAD NILIMA V
权利人:UNIV ALASKA FAIRBANKS; HULLAVARAD SHIVA S; HULLAVARAD NILIMA V
摘要:In one aspect, the invention relates to interconnected networks of transition metal oxide microspheres and nano wires. Thus, disclosed are compositions comprising an interconnected network of transition metal oxide microspheres and nanowires, programmable conductive pathways, and devices for detecting an environmental influence onto a sensor comprising same. Also disclosed are direct vapor phase processes for synthesizing same. In one aspect, an interconnected network is fabricated in a single operation. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

专利号:US-9556123-B2
优先权日:2004-07-19
标题:Synthesis of triethylenetetramines
发明人:JONAS MARCO; VAULONT IRENE; SOI ANTONIO; SCHMIDT GUNTHER
权利人:PHILERA NEW ZEALAND LTD
摘要:Methods and intermediates for synthesizing triethylenetetramine and salts thereof, as well as novel triethylenetetramine salts and their crystal structure, and triethylenetetramine salts of high purity.

专利号:US-9757463-B2
优先权日:2012-06-15
标题 :Linear polyester and semi-linear glycidol polymer systems: formulation and synthesis of novel monomers and macromolecular structures
发明人:HARTH EVA M; BEEZER DAIN B; LI GUANGZHAO; SPEARS BENJAMIN R; STEVENS DAVID M
权利人:UNIV VANDERBILT
摘要:Disclosed herein are glycidol-based polymers, nanoparticles, and methods related thereto useful for drug delivery. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

专利号:US-2021154202-A1
优先权日:2018-04-17
标 题:Synthesis of dentimol, an antiglaucoma drug
发明人:LANCINA MICHAEL; WANG JUAN; YANG HU
权利人:UNIV VIRGINIA COMMONWEALTH
摘要:Compounds, comprising a selective β-blocker coupled to a PAMAM dendrimer via a flexible spacer, and compositions containing the compounds, are provided. Methods of making and using the compounds and compositions for the treatment of glaucoma and other maladies are also provided.
天津市世和科技发展有限公司
⚠️ 未注册 · 未认证企业
⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
数据来源于公开网络搜索,平台未作核实,请自行辨别。
🏢敬请 企业认领
🏬开设公司展台
📢获取免费会员权益
🎖️点亮专属注册企业标签
📇展现公司完整信息 样本查看立即注册认领 →
网址: http://www.harmonyworld.biz
电话: 086-22-23697098👤
📞天津市世和科技发展有限公司 ⚠️参考联系方式

销售电话:086-22-23697098
邮箱:info@harmonyworld.biz
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

⚠️ 未注册 · 未认证企业
注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
第 1 / 1 页
现货

供应商参考报价(招募中)

品牌试剂参考报价(招募中)

📌 第三方产品分析报告

✅ COA系统入驻 | 共享模式

主要参考文献


1: Fang Y, Ling Z, Sun X. Fixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol. Drug Des Devel Ther. 2015 May 13;9:2617-25. doi: 10.2147/DDDT.S80338. eCollection 2015. Review.
2: Radcliffe NM. The impact of timolol maleate on the ocular tolerability of fixed-combination glaucoma therapies. Clin Ophthalmol. 2014 Dec 12;8:2541-9. doi: 10.2147/OPTH.S76053. eCollection 2014. Review.
3: Lorenz K, Pfeiffer N. Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma. Expert Opin Pharmacother. 2014 Oct;15(15):2255-62. doi: 10.1517/14656566.2014.955471. Epub 2014 Aug 29. Review. Erratum in: Expert Opin Pharmacother. 2014 Nov;15(16):2473. doi: 10.1016/j.optom.2013.06.004. Epub 2013 Aug 2. Review.

合成参考文献


摘要:Compound: 2-Propanol, 1-[(1,1-dimethylethyl)amino]-3-[[4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl]oxy]-, (2S)-, (2Z)-2-butenedioate (2:1) (salt)
📝 需求与反馈
尽可能描述清楚需求与问题信息
×

通知